Infinity Pharma Shares Rebound Over $22 Following Phase I Data on IPI-145
Posted on December 10, 2012 at 10:25 AM EST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies. Preliminary data from the study showed that IPI-145 was well tolerated to date